| pubmed-article:11241016 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0035647 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0004238 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0019139 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0206460 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0013778 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0205253 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0010187 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:11241016 | lifeskim:mentions | umls-concept:C0449445 | lld:lifeskim |
| pubmed-article:11241016 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:11241016 | pubmed:dateCreated | 2001-3-12 | lld:pubmed |
| pubmed-article:11241016 | pubmed:abstractText | An alternative clinical management strategy and cost analysis model is presented for patients with atrial fibrillation of >2 days' duration who may benefit from immediate cardioversion with self-administered low-molecular-weight heparin (enoxaparin) as a bridge antithrombotic therapy to warfarin, after a negative transesophageal echo-cardiography (TEE) screening for thrombus. Assuming no difference in stroke or bleeding rates, our cost minimization model shows that the TEE-guided enoxaparin treatment costs are $1353 lower per patient than an intravenous unfractionated heparin approach. Sensitivity analyses for stroke and bleeding reveal that the treatment-cost economic dominance of the TEE-guided enoxaparin approach may be enhanced by an expected improvement in clinical outcome. | lld:pubmed |
| pubmed-article:11241016 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11241016 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11241016 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11241016 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11241016 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11241016 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11241016 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:11241016 | pubmed:issn | 0894-7317 | lld:pubmed |
| pubmed-article:11241016 | pubmed:author | pubmed-author:ShahAA | lld:pubmed |
| pubmed-article:11241016 | pubmed:author | pubmed-author:MurrayR DRD | lld:pubmed |
| pubmed-article:11241016 | pubmed:author | pubmed-author:KleifA DAD | lld:pubmed |
| pubmed-article:11241016 | pubmed:author | pubmed-author:BashirMM | lld:pubmed |
| pubmed-article:11241016 | pubmed:author | pubmed-author:GrimmR ARA | lld:pubmed |
| pubmed-article:11241016 | pubmed:author | pubmed-author:DeitcherS RSR | lld:pubmed |
| pubmed-article:11241016 | pubmed:author | pubmed-author:JasperS ESE | lld:pubmed |
| pubmed-article:11241016 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11241016 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:11241016 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11241016 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11241016 | pubmed:pagination | 200-8 | lld:pubmed |
| pubmed-article:11241016 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:meshHeading | pubmed-meshheading:11241016... | lld:pubmed |
| pubmed-article:11241016 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11241016 | pubmed:articleTitle | Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. | lld:pubmed |
| pubmed-article:11241016 | pubmed:affiliation | Department of Cardiology, Cardiovascular Imaging Center; the Department of Vascular Medicine, Clinical Thrombosis Section; and Biostatistics and Epidemiology; The Cleveland Clinic Foundation. | lld:pubmed |
| pubmed-article:11241016 | pubmed:publicationType | Journal Article | lld:pubmed |
